Sumatriptan Succinate Tablets

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

DLA TROOP SUPPORT

Contract Value

Not provided

Codes & Classification
Solicitation Number

SPE2D223R0003

NAICS

325412 - Pharmaceutical Preparation Manufacturing

Classification Code

6505

Additional Details
Set Aside

None

Place of Performance

Carole Park, Australian Capital Territory, AUSTRALIA

SourceSAM
Documents5
The Defense Logistics Agency (DLA) Troop Support, a federal office under the Department of Defense, has issued an award notice pertaining to the ongoing procurement of Sumatriptan Succinate Tablets. This notice, identified by procurement number SPE2D223R0003, announces the execution of Option Year Three (3) under contract SPE2D223D0009, which will be effective from July 25, 2026, through July 24, 2027. The modification ensures the continued supply of this critical pharmaceutical product for the specified period. The scope of this procurement centers on the manufacturing and delivery of Sumatriptan Succinate Tablets, a medication commonly used in the treatment of migraine headaches. The requirement falls under NAICS code 325412, which covers Pharmaceutical Preparation Manufacturing, and is further classified under Product Service Code 6505, indicating drugs and biologicals. The place of performance is designated as Carole Park, located in the Australian Capital Territory, Australia, reflecting the global sourcing capabilities of the DLA to meet the needs of U.S. defense operations. The intended outcome of this contract modification is to maintain an uninterrupted supply chain for Sumatriptan Succinate Tablets, supporting the health and readiness of military personnel and other authorized recipients. Contractors engaged in this effort are expected to adhere to stringent quality standards and regulatory requirements associated with pharmaceutical manufacturing and delivery. The DLA Troop Support office serves as the contracting entity, overseeing all aspects of contract administration and performance. Key contacts for this procurement include Nancy Fernandez ([email protected], 215-737-4955) and Jason Wray ([email protected], 215-737-0614), who can provide further information regarding contract specifics and ongoing requirements. This award notice is currently active and was posted on January 7, 2026. Interested parties can access additional details and related attachments via the official SAM.gov opportunity listing at https://sam.gov/opp/85b7ff1081c64b21a637de13d1712852/view. Contractors considering participation in future option years or related opportunities should note the focus on pharmaceutical manufacturing capabilities, compliance with federal acquisition regulations, and the ability to deliver to international locations. No set-aside requirements or special considerations are specified in this notice. The core elements of this procurement—consistent supply, regulatory compliance, and quality assurance—will remain constant throughout the contract lifecycle.